These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11770280)

  • 41. Osteoporosis in elderly: prevention and treatment.
    Srivastava M; Deal C
    Clin Geriatr Med; 2002 Aug; 18(3):529-55. PubMed ID: 12424871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. When do bisphosphonates make the most sense?
    Winzenberg T; Jones G
    J Fam Pract; 2011 Jan; 60(1):18-28. PubMed ID: 21209974
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Once-a-week risedronate (actonel).
    Med Lett Drugs Ther; 2002 Oct; 44(1141):87-8. PubMed ID: 12381968
    [No Abstract]   [Full Text] [Related]  

  • 45. Parathyroid hormone.
    Madore GR; Sherman PJ; Lane JM
    J Am Acad Orthop Surg; 2004; 12(2):67-71. PubMed ID: 15089079
    [No Abstract]   [Full Text] [Related]  

  • 46. [Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
    Adachi JD
    MMW Fortschr Med; 2004 Aug; 146(31-32):53. PubMed ID: 15529719
    [No Abstract]   [Full Text] [Related]  

  • 47. Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
    Watts NB
    Osteoporos Int; 2001 Dec; 12 Suppl 3():S17-22. PubMed ID: 11846337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonates.
    Lambrinoudaki I; Christodoulakos G; Botsis D
    Ann N Y Acad Sci; 2006 Dec; 1092():397-402. PubMed ID: 17308164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fracture protection in osteoporosis with risedronate.
    Boonen S; Vanderschueren D
    Hosp Med; 2004 Sep; 65(9):535-40. PubMed ID: 15449490
    [No Abstract]   [Full Text] [Related]  

  • 50. [In response to the article by F. Trémollières. Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: bisphosphonates].
    Jamin C
    Gynecol Obstet Fertil; 2002 Jun; 30(6):551. PubMed ID: 12146160
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmacologic therapy for the treatment and prevention of osteoporosis.
    McClung B; McClung M
    Nurs Clin North Am; 2001 Sep; 36(3):433-40, viii. PubMed ID: 11532658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Combination therapy of bisphosphonate and estrogen for osteoporosis].
    Ohta H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():470-4. PubMed ID: 15035173
    [No Abstract]   [Full Text] [Related]  

  • 53. Risedronate: a new oral bisphosphonate.
    Roll KT
    Clin Ther; 2002 May; 24(5):835-6. PubMed ID: 12075950
    [No Abstract]   [Full Text] [Related]  

  • 54. Summaries for patients. Drug therapy for osteoporosis.
    Ann Intern Med; 2008 May; 148(9):I28. PubMed ID: 18458273
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term experience with alendronate in the treatment of osteoporosis.
    Hochberg MC; Rizzoli R
    Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
    Kherani RB; Papaioannou A; Adachi JD
    Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
    Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC
    Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
    Nahleh Z; Abrams J; Bhargaval A; Nirmal K; Graff JJ
    Clin Breast Cancer; 2010 Dec; 10(6):459-64. PubMed ID: 21147689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral antiresorptive therapy.
    Pande I; Hosking DJ
    Curr Osteoporos Rep; 2004 Dec; 2(4):116-22. PubMed ID: 16036092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.